Joanna Canham

Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML

Jad Othman, Nicola Potter, Adam Ivey et al. · Blood · 2024 · 79 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +11

Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission

Jad Othman, Nicola Potter, Adam Ivey et al. · Blood · 2024 · 77 citations · Full text

Medicine, Molecular Medicine, Transplant Immunology +3

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Jad Othman, Charlotte S. Wilhelm-Benartzi, Richard Dillon et al. · Blood Advances · 2023 · 54 citations · Full text

Medicine, Hematology, Oncology +17

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma

Somnath Mukherjee, Sarah Gwynne, David Sebag‐Montefiore et al. · European Journal of Cancer · 2017 · 44 citations · Full text

Medicine, Oncology, Surgery +17

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman et al. · Journal of Clinical Oncology · 2024 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15